Achilles Therapeutics plc (ACHL)
Company Info
Highlights
$63.22M
-$1.66
-$1.18M
-$37.04M
$0.63 - $1.51
$0.50
1.90%
0.23
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Achilles Therapeutics plc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
ACHL
N/A
N/A
N/A
N/A
N/A
N/A
^GSPC (Benchmark)
-3.70%
13.67%
-5.18%
9.18%
14.14%
10.43%
Monthly Returns
The table below presents the monthly returns of ACHL, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -0.88% | 22.12% | 7.25% | 29.82% | |||||||||
| 2024 | 4.61% | 41.94% | -5.30% | -40.00% | 22.67% | -11.41% | 1.72% | -13.15% | 41.67% | -1.96% | 7.50% | 6.05% | 28.23% |
| 2023 | 37.78% | -11.29% | -12.95% | -13.32% | 20.48% | -5.48% | 7.91% | -8.80% | -2.18% | -5.48% | -3.95% | 7.63% | -1.22% |
| 2022 | -24.15% | -12.89% | -11.18% | -24.49% | 12.61% | 0.80% | 1.19% | 14.12% | -22.34% | -14.60% | 4.66% | -55.45% | -82.04% |
| 2021 | -6.04% | -18.78% | -22.49% | -40.45% | 16.30% | 14.90% | -21.18% | -16.94% | -1.76% | -69.73% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of ACHL is 74, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Achilles Therapeutics plc (ACHL) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the Achilles Therapeutics plc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Achilles Therapeutics plc was 96.08%, occurring on Sep 11, 2024. The portfolio has not yet recovered.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -96.08% | Apr 7, 2021 | 864 | Sep 11, 2024 | — | — | — |
| -9.85% | Apr 1, 2021 | 2 | Apr 5, 2021 | 1 | Apr 6, 2021 | 3 |
Volatility
Volatility Chart
The current Achilles Therapeutics plc volatility is 4.93%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Achilles Therapeutics plc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Achilles Therapeutics plc, comparing actual results with analytics estimates. The company met analyst expectations for EPS in the past quarter.
Valuation
The Valuation section provides an overview of how Achilles Therapeutics plc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for ACHL relative to other companies in the Biotechnology industry. Currently, ACHL has a P/S ratio of 0.0. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for ACHL in comparison with other companies in the Biotechnology industry. Currently, ACHL has a P/B value of 0.6. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |